• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Michael Klagsbrun, PhD


  • Akino T, Han X, Nakayama H, McNeish BL, Zurakowski D, Mammoto A, Klagsbrun M, Smith E.Netrin-1 promotes medulloblastoma cell invasiveness and angiogenesis, and demonstrates elevated expression in tumor tissue and urine of pediatric medulloblastoma patients.Cancer Res. 2014 May 8.
  • Procaccia V, Nakayama H, Shimizu A, Klagsbrun M.Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility.Biochem Biophys Res Commun. 2014 Apr 20.
  • Coma S, Allard-Ratick M, Akino T, van Meeteren LA, Mammoto A, Klagsbrun M.GATA2 and Lmo2 control angiogenesis and lymphangiogenesis via direct transcriptional regulation of neuropilin-2.Angiogenesis. 2013 Oct;16(4):939-52.
  • Shimizu A, Nakayama H, Wang P, K├Ânig C, Akino T, Sandlund J, Coma S, Italiano JE, Mammoto A, Bielenberg DR, Klagsbrun M.Netrin-1 promotes glioblastoma cell invasiveness and angiogenesis by multiple pathways including activation of RhoA, cathepsin B, and cAMP-response element-binding protein.J Biol Chem. 2013 Jan 25;288(4):2210-22.
  • Coma S, Shimizu A, Klagsbrun M.Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2.Cell Adh Migr.;5(3):266-75.
  • Dudley AC, Udagawa T, Melero-Martin JM, Shih SC, Curatolo A, Moses MA, Klagsbrun M.Bone marrow is a reservoir for pro-angiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors.Blood. 2010 Oct 28;116(17):3367-71.
  • Geretti E, van Meeteren LA, Shimizu A, Dudley AC, Claesson-Welsh L, Klagsbrun M.A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression.Mol Cancer Res. 2010 Aug;8(8):1063-73.
  • Klagsbrun M, Shimizu A.Semaphorin 3E, an exception to the rule.J Clin Invest. 2010 Aug 2;120(8):2658-60.
  • Coma S, Amin DN, Shimizu A, Lasorella A, Iavarone A, Klagsbrun M.Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F.Cancer Res. 2010 May 1;70(9):3823-32.
  • Dudley AC, Klagsbrun M.Tumor endothelial cells join the resistance.Clin Cancer Res. 2009 Aug 1;15(15):4787-9.
  • Dudley AC,Klagsbrun M.Tumor endothelial cells have features of adult stem cells.Cell Cycle. 2009 Jan 15;8(2):236-8.
  • Dudley AC,Khan ZA,Shih SC,Kang SY,Zwaans BM,Bischoff J,Klagsbrun M.Calcification of multipotent prostate tumor endothelium.Cancer Cell. 2008 Sep 9;14(3):201-11.
  • Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M.Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.Microvasc Res. 2008 May;76(1):15-22.
  • Geretti E, Shimizu A, Klagsbrun M.Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis.Angiogenesis. 2008 Mar;11(1):31-39. Review.
  • Bielenberg DR, Klagsbrun M.Targeting endothelial and tumor cells with semaphorins.Cancer Metastasis Rev. 2007 Dec;26(3-4):421-31. Review.
  • Geretti E, Shimizu A, Kurschat P, Klagsbrun M.Site-directed mutagenesis in the B-neuropilin-2 domain selectively enhances its affinity to VEGF165, but not to semaphorin 3F.J Biol Chem. 2007 Aug 31;282(35):25698-707.
  • Klagsbrun M, Eichmann A.A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis.Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):535-48.
  • Hida K, Klagsbrun M.A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities.Cancer Res. 2005 Apr 1;65(7):2507-10.
  • Nishi E, Klagsbrun M.Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a mediator of multiple physiological and pathological pathways.Growth Factors. 2004 Dec;22(4):253-60.
  • Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M.Tumor-associated endothelial cells with cytogenetic abnormalities.Cancer Res. 2004 Nov 15;64(22):8249-55.
  • Goishi K, Klagsbrun M.Vascular endothelial growth factor and its receptors in embryonic zebrafish blood vessel development.Curr Top Dev Biol. 2004;62:127-52.
  • Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, Klagsbrun M.Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype.J Clin Invest. 2004 Nov;114(9):1260-71.
  • Bovenkamp DE, Goishi K, Bahary N, Davidson AJ, Zhou Y, Becker T, Becker CG, Zon LI, Klagsbrun M.Expression and mapping of duplicate neuropilin-1 and neuropilin-2 genes in developing zebrafish.Gene Expr Patterns. 2004 Jul;4(4):361-70.
  • Goishi K, Lee P, Davidson AJ, Nishi E, Zon LI, Klagsbrun M.Inhibition of zebrafish epidermal growth factor receptor activity results in cardiovascular defects.Mech Dev. 2003 Jul;120(7):811-22.